Fig. 5: MECOM and ETS2 are required for sustaining the oncogenic capacity of CRC cells. | Cell Death & Disease

Fig. 5: MECOM and ETS2 are required for sustaining the oncogenic capacity of CRC cells.

From: A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer

Fig. 5

A Representative photos and quantification results of monolayer colony-formation assay for HCT15 cells stably expressing shRNAs targeting MECOM, ETS2 or a non-targeting shRNA. B Representative photos and quantification results of sphere-formation assay for HT29 cells stably expressing shRNAs targeting MECOM, ETS2 or a non-targeting shRNA. C Representative photos and quantification results of transwell migration assay for Lovo cells stably expressing shRNAs targeting MECOM, ETS2 or a non-targeting shRNA. *p < 0.05; **p < 0.01; n.s. non-significant. D Schematic diagram showing the mechanism underlying the activation of oncogenic ETS2 by a distal SE in IBD and CRC. Please refer to the text for details.

Back to article page